Skip to main content
Top

Open Access 29-03-2025 | Insulins

Insulin icodec: A novel once-weekly formulation for the treatment of type 1 and type 2 diabetes mellitus

Authors: David Q. Pham, John Andraos, Joelle Ayoub

Published in: Reviews in Endocrine and Metabolic Disorders

Login to get access

Abstract

Insulin icodec is a novel once-weekly basal insulin analog subcutaneous injection seeking approval by the United States Food and Drug Administration (FDA) for use in both type 1 and type 2 diabetes mellitus. The mission of this manuscript is to provide a thorough overview of insulin icodec’s clinical trials that were involved in its approval as well as review its pharmacology, pharmacokinetics, adverse effects, drug interactions, dosage recommendations, and regulatory issues. This article includes a thorough review of insulin icodec’s safety and efficacy in type 1 and type 2 diabetes mellitus including its pharmacokinetic and pharmacodynamic profile. A systematic search of the electronic database of PubMed from inception until December 2024 using MeSH keywords was completed. Keywords used were icodec, insulin, type 1 diabetes, and type 2 diabetes. Overall, 14 clinical trials were identified and reviewed. The majority of the trials reviewed showed decreases in A1C as primary endpoints and non-inferiority and superiority with insulin icodec versus the comparator. In select studies, mild hypoglycemia was more evident in subjects taking insulin icodec versus the comparator but no other concerns were identified. The reviewed literature showed similar and sometimes improved glycemic control when insulin icodec was compared to other long-acting insulins both in insulin-naive and previously insulin-treated patients. Hypoglycemia was similar or slightly increased with insulin icodec when compared to other long acting insulins. Overall, icodec is a useful, new formulation of basal insulin that allows for less injections, improved compliance, and potentially improved glycemic control providing a new tool to practitioners managing patients with diabetes who need to be on insulin.
Literature
2.
go back to reference Polonsky WH, Fisher L, Hessler D, et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metabol. 2011;13:144–9.CrossRef Polonsky WH, Fisher L, Hessler D, et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metabol. 2011;13:144–9.CrossRef
3.
go back to reference Abuelazm M, Ibrahim A, Khlidj Y, et al. Once-weekly insulin icodec versus once-daily long-acting insulin for type 2 diabetes: A meta-analysis of randomized controlled trials. J Endocr Soc. 2024;8:1–13.CrossRef Abuelazm M, Ibrahim A, Khlidj Y, et al. Once-weekly insulin icodec versus once-daily long-acting insulin for type 2 diabetes: A meta-analysis of randomized controlled trials. J Endocr Soc. 2024;8:1–13.CrossRef
17.
go back to reference Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11:414–25. https://doi.org/10.1016/S2213-8587(23)00093-1.CrossRefPubMed Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11:414–25. https://​doi.​org/​10.​1016/​S2213-8587(23)00093-1.CrossRefPubMed
19.
go back to reference Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401:1929–40. https://doi.org/10.1016/S0140-6736(23)00520-2.CrossRefPubMed Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401:1929–40. https://​doi.​org/​10.​1016/​S0140-6736(23)00520-2.CrossRefPubMed
Metadata
Title
Insulin icodec: A novel once-weekly formulation for the treatment of type 1 and type 2 diabetes mellitus
Authors
David Q. Pham
John Andraos
Joelle Ayoub
Publication date
29-03-2025
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-025-09960-x

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more